Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran.
OBJECTIVE
To investigate the possible mechanisms underlying the liver enzyme elevations seen during clinical studies of long-term treatment (>35 days) with ximelagatran, and investigate the usefulness of pre-clinical in vitro systems to predict drug-induced liver effects.


METHODS
Ximelagatran and its metabolites were tested for effects on cell viability, mitochondrial function, formation of reactive metabolites and reactive oxygen species, protein binding, and induction of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) gene expression or nuclear orphan receptors. Experimental systems included fresh and cryopreserved hepatocytes, human hepatoma cell lines (HepG2 and HuH-7) and subcellular human liver fractions.


RESULTS
Loss of cell viability was only seen in HepG2 cells at ximelagatran concentrations 100 microM and in cryopreserved human hepatocytes at 300 microM, while HuH-7 cells were not affected by 24 h exposure at up to 300 microM ximelagatran. Calcium homeostasis was not affected in HepG2 cells exposed to ximelagatran up to 300 microM for 15 min. There was no evidence for the formation of reactive metabolites when cell systems were exposed to ximelagatran. ALT and AST expression in human hepatoma cell lines were also unchanged by ximelagatran. Mitochondrial functions such as respiration, opening of the transition pore, mitochondrial membrane depolarization and beta-oxidation were not affected by ximelagatran or its metabolites.


CONCLUSIONS
Ximelagatran at concentrations considerably higher than that found in plasma following therapeutic dosing had little or no effect on cellular functions studied in vitro. The in vitro studies therefore did not elucidate the mechanism by which ximelagatran induces liver effects in humans, possibly because of limitations in the experimental systems not reflecting characteristics of the human hepatocyte, restricted exposure time, or because the primary mechanism for the observed clinical liver effects is not on the parenchymal liver cell.
Kenne
Kerstin
K
Safety Assessment, AstraZeneca R&D Södertälje, S-151 85 Södertälje, Sweden.
Skanberg
Inger
I
Glinghammar
Bjorn
B
Berson
Alain
A
Pessayre
Dominique
D
Flinois
Jean-Pierre
JP
Beaune
Philippe
P
Edebert
Irene
I
Pohl
Cecilia Diaz
CD
Carlsson
Stefan
S
Andersson
Tommy B
TB
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D000975:Antioxidants / Q000378:metabolism; D017209:Apoptosis / Q000187:drug effects; D001384:Azetidines / Q000378:metabolism / Q000633:toxicity*; D001596:Benzylamines / Q000378:metabolism / Q000633:toxicity*; D002118:Calcium / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000473:pathology; D002460:Cell Line; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology*; D002853:Chromatography, Liquid; D015925:Cryopreservation; D005343:Fibrinolytic Agents / Q000378:metabolism / Q000633:toxicity*; D005434:Flow Cytometry; D022781:Hepatocytes / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D013058:Mass Spectrometry; D008930:Mitochondria, Liver / Q000187:drug effects / Q000378:metabolism; D009336:Necrosis; D010539:Permeability; D011237:Predictive Value of Tests; D051381:Rats; D017382:Reactive Oxygen Species / Q000378:metabolism; D013347:Subcellular Fractions / Q000187:drug effects / Q000378:metabolism; D013917:Thrombin / Q000037:antagonists & inhibitors*
D000975:Antioxidants; D001384:Azetidines; D001596:Benzylamines; D005343:Fibrinolytic Agents; D017382:Reactive Oxygen Species; C426686:ximelagatran; D000255:Adenosine Triphosphate; D013917:Thrombin; D002118:Calcium